BAJAJ BROKING

Notification
No new Notification messages
Denta Water & Infra Solutions IPO is Open!
Apply for the Denta Water & Infra Solutions IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Dr Reddy's Q3 Results FY24-25 Highlights, Revenue Up 16% YoY, Net Profit at ₹1,413.3 Crore (Consolidated)

Dr Reddy's Laboratories Ltd announced its consolidated financial results for Q3 FY24-25 on 23rd January 2025. The unaudited consolidated results, prepared under IFRS, highlighted robust revenue growth and steady profitability. Dr Reddy's Laboratories reported a 2% year-on-year increase in its consolidated net profit for the December quarter, amounting to ₹1,413 crore, compared to ₹1,379 crore in the same period last year. 

The revenue from operations for Q3 FY25 was ₹8,359 crore, reflecting a 16% growth from ₹7,215 crore in the corresponding quarter of the previous financial year. The profit after tax (PAT) is attributable to the equity holders of the company.

DR. REDDY S LABORATORIES

Trade

1224.4-65.00 (-5.04 %)

Updated - 24 January 2025
1252.65day high
DAY HIGH
1203.50day low
DAY LOW
7082467
VOLUME (BSE)

Key Highlights/Quick Insights

  • Revenue Growth: ₹8,358.6 crore, a 16% YoY increase.

  • Net Profit: ₹1,413.3 crore, reflecting a 2% YoY growth.

  • Gross Margin: Improved slightly to 58.7% from 58.5% in Q3 FY24.

  • SG&A Expenses: ₹2,411.7 crore, up 19% YoY.

  • EBITDA: ₹2,298.2 crore, representing 27.5% of revenue.

  • R&D Spend: ₹665.8 crore, accounting for 8.0% of revenue.

Quarterly - Dr Reddy's Q3 Results FY24-25

Dr Reddy’s consolidated revenue rose to ₹8,358.6 crore, marking a robust 16% year-on-year growth. Net profit stood at ₹1,413.3 crore, driven by operational efficiency and contributions from the recently acquired Nicotine Replacement Therapy (NRT) business. The EBITDA margin remained strong at 27.5%, while R&D investments sustained innovation efforts in complex generics and biosimilars.

Segment Highlights

Global Generics

  • Revenue: ₹7,375.3 crore (+17% YoY).

    • North America: ₹3,383.4 crore (+1% YoY).

    • Europe: ₹1,209.6 crore (+143% YoY).

    • India: ₹1,346.4 crore (+14% YoY).

    • Emerging Markets: ₹1,435.8 crore (+12% YoY).

  • Growth was led by contributions from the NRT portfolio and new product launches.

Pharmaceutical Services and Active Ingredients (PSAI)

  • Revenue: ₹821.9 crore (+5% YoY).

Others

  • Revenue: ₹161.4 crore (+33% YoY).

Sector Expectations for Dr Reddy’s Q3 Results FY24-25

Dr Reddy’s 16% revenue growth aligns with the pharmaceutical sector's optimistic projections, bolstered by increasing demand for generics and new launches. The 2% YoY increase in net profit reflects resilience amidst rising costs in SG&A and R&D.

Management Commentary

Co-Chairman & MD, G.V. Prasad, commented:

“We delivered double-digit growth aided by our newly acquired NRT business, new launches, and improved operational efficiencies. We remain committed to addressing patient needs by advancing healthcare through access, affordability, and innovation”

Outlook

The key priorities for the future include:

  1. NRT Integration: Maximising value from the Nicotine Replacement Therapy business.

  2. Product Launches: Expanding the pipeline with complex generics and biosimilars.

  3. Geographical Growth: Strengthening presence in North America, Europe, and Emerging Markets.

  4. Cost Efficiency: Enhancing operational and manufacturing efficiencies.

  5. Healthcare Access: Continuing focus on affordability and innovation globally.

Dr Reddy's Laboratories Limited - Unaudited Consolidated Financial Results

(All amounts in ₹ millions)

Sl No. 

Particulars

Quarter Ended

Nine Months Ended

Year Ended

31.12.2024 

30.09.2024 

31.12.2023 

31.12.2024

31.12.2023 

31.03.2024 

(Unaudited)

(Unaudited)

(Unaudited)

(Unaudited)

(Unaudited)

(Audited)

1

Revenues

83,586 

80,162 

72,148 

240,475 

208,334 

279,164 

2

Cost of Revenues

34.534 

32,393

29.945 

97.310

86,210 

115,557

3

Gross Profit (I - 2)

49,052

47,769

42,203

143,165

122,124

163,607

4

Selling, General and Administrative Expenses

24,117

23,007

20,228

69,815

56,725

77,201

5

Research and Development Expenses

6,658

7,271

5,565

20,122

15,996

22,873

6

Impairment of Non-Current Assets, Net

924

110

925

176

3

-

7

Other Income, Net

(439)

(984)

(967)

(1,893)

(3,543)

(4,199)

 

Total Operating Expenses

30,332

30,218

24,936

88,969

69,354

95,878

8

Results from Operating Activities (1 - 4 + 5 + 6 + 7)

18,720

17,551

17,267

54,196

52,770

67,729

 

Finance Income

798

2,312

1,357

4,545

4,090

5,705

 

Finance Expense

(818)

(757)

(394)

(2,173)

(1,118)

(1,711)

9

Finance (Expense)/Income, Net

(20)

1,555

963

2,372

2,972

3,994

10

Share of Profit of Equity Accounted Investees, Net of Tax

42

61

27

162

112

147

11

Profit Before Tax (8 + 9 + 10)

18,742

19,167

18,257

56,730

55,854

71,870

12

Tax Expense, Net

4,704

5,752

4,468

15,357

13,240

16,186

13

Profit for the Period/Year (11 - 12)

14,038

13,415

13,789

41,373

42,614

55,684

 

Attributable to:

 
 

Equity Holders of the Parent Company

14,133

12,553

13,789

40,606

42,614

55,684

 

Non-controlling Interests

(95)

862

767

-

-

-

14

Earnings Per Equity Share Attributable to Equity Shareholders of Parent

      
 

Basic Earnings Per Share of Re. 1/- Each

16.96

15.07

16.56

48.75

51.23

66.93

 

Diluted Earnings Per Share of Re. 1/- Each

16.94

15.05

16.54

48.68

51.14

66.81

Source: Dr Reddy’s Q3 Financial Results FY’24-25 Submitted on BSE

Dr Reddy’s Q3 FY25 Results Preview: Revenue Growth of 10% YoY, Flat PAT Expected

Dr Reddy's Laboratories is scheduled to announce its Q3 FY25 results on 23 January 2025. The pharmaceutical major is expected to report a 10% year-on-year (YoY) revenue growth, while profit after tax (PAT) is projected to remain flat at Rs 1,369 crore. Margins are likely to come under pressure due to subdued growth in the US base business and a decline in Revlimid sales.

Expected Dr Reddy’s Q3 FY25 Results

  • Revenue Growth: Estimated at 10% YoY to Rs 7,980 crore

  • Profit After Tax (PAT): Expected to remain flat at Rs 1,369 crore

  • EBITDA Margin: Likely to contract to 26.9% from 29.3% YoY

  • US Sales: Projected to remain stable YoY at $405-427 million

  • Domestic Sales: Expected to grow 14% YoY

  • Emerging Markets: Europe and Russia sales estimated to rise by 19% and 14% YoY, respectively

The estimates are based on analyst insights from The Economic Times and Moneycontrol.

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5300+ Cr MTF Book

icon-with-text